Press Releases

15.04.14
Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital

Biotechnology company Mucosis B.V. today announced that it entered into a long-term collaboration and license agreement with China-based Changchun BCHT Biotechnology Co (BCHT) and raised EUR 5 million, in a new financing round.
read more >

12.08.13
Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines

A safe and protective intranasal RSV vaccine (SynGEM®) based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles

Biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal PLOS ONE of preclinical data showing that its innovative SynGEM® is safe and protective in animal models.
read more >

16.05.13
Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate

Dutch biotechnology company Mucosis B.V. presented preclinical data at the MODERN VACCINES ADJUVANTS FORMULATION conference (MVAF 2013) in Lausanne, Switzerland, demonstrating that SynGEM® provides protection against RSV both in the mouse and cotton rat model while no “enhanced disease” symptoms were observed. SynGEM® is a novel Mimopath®-based mucosal RSV vaccine candidate that will be administered through simple intranasal delivery.
read more >

08.10.12
Mucosis signs Research and License Option Agreement with Crucell

Groningen, the Netherlands, Oct 8, 2012 - Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it has signed a Research and License Option Agreement with Crucell Holland B.V. ("Crucell"), the Dutch developer of vaccines and antibodies. Crucell is one of the Pharmaceutical Companies of Johnson & Johnson.
read more >

25.09.12
ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant

Biotech companies ExpreS²ion Biotechnologies and Mucosis, along with University of Copenhagen today announced that they have been awarded a Eurostars™ grant with a total budget of over €1 million for the pre-clinical development of an innovative placental malaria vaccine.
read more >

18.09.12
Mucosis Appoints Thomas Johnston to CEO

Mucosis B.V., the Dutch clinical-stage biotechnology company developing mucosal vaccines, today announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately. Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.
read more >

10.05.12
Mucosis announces positive proof-of-concept data for Mimopath® platform in humans

Dutch vaccine development company Mucosis B.V. today announced Phase I clinical data providing proof-of-concept that Mimopath®-based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract.
read more >

03.05.12
Mucosis announces publication of preclinical data demonstrating superior protection by mucosally administered Mimopath®-based influenza vaccines

Mimopath©-based influenza vaccine protects against both homologous and heterologous challenge
read more >

15.11.11
Mucosis announces new scientific advisory board

Dutch biotechnology company Mucosis B.V. today announced that it has appointed professors Jiri Mestecky, M.D., Ph.D.; Willem van Eden, M.D., Ph.D.; and Peter J. Openshaw, M.B., B.S., Ph.D., F.Med.Sci., to its newly formed Scientific Advisory Board.
read more >

17.05.11
Mucosis appoints Thomas Johnston as Chief Business Officer

Dutch biotechnology company Mucosis B.V. today announced the appointment of Thomas Johnston as Chief Business Officer. In this role he will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
read more >

21.03.11
Mucosis starts clinical study with its lead product, Flugem®

Dutch biotechnology company Mucosis B.V. today announced the start of a Phase 1 clinical study with its lead product FluGEM®, a novel improved influenza vaccine for the elderly. It is the first-ever study in man with a vaccine candidate based on Mimopath™, a proprietary platform technology for developing more potent vaccines.
read more >

12.11.10
Dr. Barry Buckland joins the Mucosis supervisory board

Dutch biotechnology company Mucosis B.V. announced today that Dr. Barry Buckland was elected to its Supervisory Board. Dr Buckland brings extensive experience in vaccine design and development.
read more >

28.09.10
Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company’s Mimopath™ technology in oral vaccines to prevent and treat severe diarrhea.
read more >

23.09.10
John Lambert elected chairman of Mucosis

Dutch biotechnology company Mucosis B.V. announced today that John Lambert was elected as member and chair of its Supervisory Board. Having held various key positions at pharmaceutical and biotech companies in both the United States and Europe, Mr. Lambert brings exceptional vaccine industry experience to Mucosis.
read more >

31.05.10
Mucosis receives financial support from the Dutch government for its FluGEM program

Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM®, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM® clinical development program is concluded successfully.
read more >

27.04.10
Mucosis appoints Dr. Roberto Grimaldi as chief medical officer

Dutch vaccine development company MUCOSIS B.V. announced today that Dr. Roberto Grimaldi, MD was appointed Chief Medical Officer at Mucosis. Dr. Grimaldi is an accomplished executive and consultant to the vaccine industry who brings over 25 years of experience. As an expert on vaccine development he will lead the Mucosis development programs into clinical trials in the near future.
read more >

22.09.09
Mucosis receives key US patent covering its Mimopath® technology

Dutch biotechnology company MUCOSIS B.V. announced today that it has been granted a key patent by the United States Patent and Trademark Office for its Mimopath® technology, a new invention in the field of vaccines. Patents for this proprietary technology have also been granted in the European Union and China.
read more >

28.01.09
MUCOSIS B.V. and PATH start development of pneumococcal vaccines

Dutch biotechnology company Mucosis B.V. and the global nonprofit organization PATH today announced a partnership to advance the development of pneumococcal vaccine candidates.
read more >

15.12.08
MUCOSIS B.V. and TNO announce flu vaccine research and development partnership.

Dutch biotechnology company Mucosis B.V. and the Netherlands Organization for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop an intranasal influenza vaccine.
read more >

10.12.08
News article in “Het Financieele Dagblad”.

Geen product, geen winst, maar wel dromen van een multinational
(No product or profit yet, but having a dream of a multinational enterprise)

‘Dit is het hart van ons bedrijf.’ Bestuursvoorzitter Govert Schouten van het Groningse biotechbedrijf Mucosis staat in een laboratorium. Rechts warmhoudkasten, links koelkasten, op tafel staat een vreemd apparaat waar een aantal slangetjes uit komt. Uit een koelkast pakt hij een reageerbuisje met troebele vloeistof. Dat zijn behandelde melkzuurbacteriën, dé technologie die het bedrijfje groot moet maken.
read more >

06.11.08
Mucosis B.V. appoints Dr. Govert Schouten as CEO.

Dutch biotechnology company Mucosis B.V. today announced the appointment
of Dr. Govert Schouten to the position of Chief Executive Officer.

"We are very pleased to have a person with Dr. Schouten’s business and strategic
background join Mucosis," said Dr. Willem Hazenberg, chairman of the supervisory
board of Mucosis and partner at Mucosis’s lead investor BioGeneration Ventures B.V.
"His extensive experience in the vaccine industry will make an important contribution to Mucosis's ambitious growth strategy for the coming years”.
read more >

10.09.07
Mucosis raises € 3 million in first financinground

Groningen, 10 September 2007. Dutch-based vaccine development company Mucosis BV today announced the successful completion of a € 3 million first round of financing. A consortium consisting of BioGeneration Ventures (lead investor), MedSciences Capital, and NV NOM, Investment and Development Agency for the Northern Netherlands, participated in this equity investment.
read more >

15.04.14 Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital
more >

12.08.13 Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
more >

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >

25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >

18.09.12 Mucosis Appoints Thomas Johnston to CEO
more >